Selective inhibition of PfATP6 by artemisinins and identification of new classes of inhibitors after expression in yeast

Catherine M. Moore^{1*}, Jigang Wang², Qingsong Lin², Pedro Ferreira³, Mitchell A. Avery⁴, Khaled Elokely⁵, Henry M. Staines^{1*}, Sanjeev Krishna^{1,6,7*}

¹ Institute for Infection and Immunity, St. George's, University of London, United Kingdom

² Department of Biological Sciences, National University of Singapore, Singapore 117543, Singapore.

³ Microbiology and Infection Research Domain, Life and Health Sciences Research Institute, School of Medicine, University of Minho, Campus de Gualtar, Portugal

⁴ University of Mississippi, School of Pharmacy, Dept. of BioMolecular Sciences, Division of Medicinal Chemistry, USA

⁵ Institute for Computational Molecular Science, and Department of Chemistry, Temple University, Philadelphia, PA 19122, United States

⁶ St. George's University Hospitals National Health Services Foundation Trust, London

⁷ Universitätsklinikum Tübingen, Tübingen, Germany

*To whom correspondence should be addressed.

Email addresses:

CMM: cmoore@sgul.ac.uk

JW: jgwang@icmm.ac.cn

QL: dbslinqs@nus.edu.sg

PF: pedroferreira@med.uminho.pt

27 MAA: mavery@olemiss.edu

28 KE: kelokely@temple.edu

29 HMS: hstaines@sgul.ac.uk

30 SK: sgjf100@sgul.ac.uk

Abstract

Treatment failures with artemisinin combination therapies (ACTs) threaten global efforts to eradicate malaria. They highlight the importance of identifying drug targets and new inhibitors and of studying how existing antimalarial classes work.

Herein we report the successful development of an heterologous expression-based compound screening tool. Validated drug target *P. falciparum* calcium ATPase6 (PfATP6) and a mammalian ortholog (SERCA1a) were functionally expressed in yeast providing a robust, sensitive, and specific screening tool. Whole-cell and *in vitro* assays consistently demonstrated inhibition and labelling of PfATP6 by artemisinins. Mutations in PfATP6 resulted in fitness costs that were ameliorated in the presence of artemisinin derivatives when studied in the yeast model.

As previously hypothesised, PfATP6 is a target of artemisinins. Mammalian SERCA1a can be mutated to become more susceptible to artemisinins. The inexpensive, low technology yeast screening platform has identified unrelated classes of druggable PfATP6 inhibitors. Resistance to artemisinins may depend on mechanisms that can concomitantly address multi-targeting by artemisinins and fitness costs of mutations that reduce artemisinin susceptibility.

Introduction

The rate of decline in global cases of malaria has diminished in recent years¹. Fortunately, artemisinin-containing antimalarial combination therapies (ACTs) continue to be effective in managing uncomplicated malaria, including in those regions with multidrug resistant parasites². Artemisinins in ACTs remain effective even when their partner drug is failing³. In the past few years decreased parasite clearance times following treatment with ACTs have been associated with decreased sensitivity of *Plasmodium falciparum* ring stages to dihydroartemisinin (DHA)⁴. Prolonged parasite clearance times in and of themselves are not associated with treatment failures if the partner drug of an ACT is effective, but concerns have been raised about the risk of artemisinin resistance^{5,6}.

Understanding how artemisinins act as antimalarials can help to optimise their use, increase insights into potential artemisinin resistance mechanisms, and help to develop them for other urgently needed indications such as their repurposing as anti-cancer⁷ or anti-SARS-CoV-2 agents⁸. Almost two decades ago, we suggested that artemisinins acted by inhibiting PfATP6, the SERCA pump of malarial parasites⁹. Several independent lines of evidence were consistent with this hypothesis, including the following observations. There are structural similarities between thapsigargin, a specific mammalian SERCA pump inhibitor, and artemisinins. Synthesis of thaperoxide that incorporates an endoperoxide bridge into thapsigargin confirmed that these structures were relatable, because antimalarial potency and inhibition of PfATP6 were simultaneously increased¹⁰. There was a positive correlation between inhibitor profiles for antimalarial action *in vitro* (whole cell assays) and after heterologous expression of PfATP6⁹. Artemisinin sensitivity in parasites transfected with PfATP6 mutant ^{L263E}PfATP6 showed increased variability in sensitivity assays, with decreased sensitivity to artemisinin and dihydroartemisinin *in ex vivo* and *in vivo* experiments¹¹. Fluorescent derivatives of artemisinin and thapsigargin co-localised in parasites¹². PfATP6 is an essential gene in parasites as attempts to knock it out are lethal¹³. Studies in unrelated systems, such as in mammalian cancer cell lines have also demonstrated inhibition of SERCA by artemisinins^{14,15}.

Heterologous expression of PfATP6 using *Xenopus* oocytes showed selective inhibition by artemisinins⁹. Others attempted to reproduce inhibition by artemisinins using purified and reconstituted PfATP6 in membrane vesicles and after expression in oocytes, but were unsuccessful¹⁶.

Our understanding of mechanisms of action of artemisinins has recently progressed through use of ‘click’ chemistry approaches. Artemisinins are alkylating agents that form covalent bonds (after activation) with their targets¹⁷. This has allowed the labelling of dozens of proteins in asexual stage *P. falciparum* and validation of some of them as potential targets of artemisinins. Two independent groups almost simultaneously identified several *P. falciparum* transporters by labelling with derivatised artemisinins. PfATP6 was included in this list of labelled proteins in both *in vivo* experiments^{18,19}.

To advance these studies, we developed a yeast functional rescue assay using a codon optimised construct of PfATP6. This robust assay allows screening and study of PfATP6 inhibitors and comparisons with mammalian SERCA, mutational analyses, biochemical studies and scaling for higher throughput investigations. We have also translated findings from heterologous expression in yeast to studies in parasites to confirm their relevance and report findings using these approaches.

Results

Screening tool development and optimisation

Saccharomyces cerevisiae (K667) is hypersensitive to extracellular calcium as endogenous P-type calcium ATPases are inactive (PMC1) or deleted (PMR1). K667 is functionally rescued with heterologous P-type calcium ATPases as described¹³. To expand the repertoire available for screening inhibitors and mutated sequences, several modifications were introduced in expression studies.

To compare with mammalian SERCA1a pump a new strain (K667::SERCA1a) was generated by transformation of K667 with plasmid pUGpd-SERCA1a. A vector-only control (K667::pUGpd) was included in experiments assessing selectivity and specificity of inhibitors. SERCA1a expression in yeast (Figure 1a) restores calcium tolerance (Figure 1b) to similar levels to that seen in Pulcini

et al. for PfATP6 (Figure 2;¹³). Sensitivity to inhibitors is more apparent when they are used to inhibit yeast growth in the presence of calcium, at concentrations approaching those maximally tolerated by a particular strain. 20-40 mM total extracellular calcium concentration is optimal for assessing inhibition of PfATP6 (Figure 3;¹³). For SERCA1a any concentration greater than 50 mM (up to 250 mM) is sufficient to monitor complete inhibition (S. Figure 1b).

We confirmed that rescue in individual yeast strains was dependent on PfATP6 or SERCA1a by using cyclopiazonic acid (CPA) as a relatively unspecific inhibitor of both pumps. Artemisinin derivatives selectively inhibit PfATP6 function leaving SERCA1a unaffected at comparable concentrations (Figure 1c) and are used to establish specificity.

Yeast expresses ABC transporters that may modulate sensitivity to inhibitors in whole cell screening assays by enhancing their efflux. We knocked out *PDR5*, a key efflux pump, to establish its contribution to sensitivity of whole cell assays to inhibitors²⁰. For *K667ΔPDR5::SERCA1a* the IC₅₀ was over two-fold lower for thapsigargin (141.8 ± 43.9 nM) compared with IC₅₀ in *K667::SERCA1a* (334.7 ± 67.5 nM; p = 0.015) (Figure 1d). The IC₅₀ values for different artemisinin derivatives in this strain of yeast (*K667ΔPDR5::PfATP6*) were 4 -11 times lower than those for the *PDR5* intact strain *K667::PfATP6* (Table 1). *K667ΔPDR5* was therefore used for subsequent experiments.

Mechanism of action investigations

Artemisinin's mode of action is not yet fully elucidated, but it alkylates multiple proteins after being activated by haem in malarial parasites and in cancer cell lines²¹. To confirm PfATP6 is alkylated by artemisinins in yeast as well as parasites, we used a biotin-derivatised dihydroartemisinin (NewChem Technologies, Figure 2a) that retains antiparasitic potency (IC₅₀ 5.0 nM ± 2.0 nM compared with dihydroartemisinin 2.5 nM ± 1.4 nM; p=0.15) to label PfATP6 or SERCA1a.

PfATP6 binding to DHA was confirmed through pull-down and western blot analyses (Figure 2b), and mass spectrometry identified several proteins alkylated by the tagged dihydroartemisinin when applied to membrane extracts

and whole yeast, including PfATP6 in K667[PfATP6] preparations. Yeast lacking PfATP6 were not labelled at the masses shown in Figure 2b (Table 2). SERCA1a could not be labelled to the same extent in parallel experiments (Figure 2c), consistent with a decreased potency of artemisinins against the native mammalian orthologue (Figure 1c). Pre-incubation of PfATP6 with excess dihydroartemisinin competed with the tagged dihydroartemisinin, preventing it from binding (Figure 2c). The addition of haem increased labelling of PfATP6 exposed to tagged dihydroartemisinin, as it does in parasites (Figure 2b and ¹⁸). Conversely, chelation of Fe³⁺ using desferrioxamine (DFO) attenuates the interactions between artemisinins and targets (Figure 2b). Immunofluorescence assays with parasites using a FITC-labelled anti-biotin antibody localised the tagged dihydroartemisinin to the area surrounding the nucleus, most likely the ER, which is where PfATP6 is localised (Figure 2d)¹³.

Compound screening

Several individual compounds and three compound sets were screened using whole cell assays: the Medicines for Malaria Venture (MMV) malaria box library²², the MMV OZ box, and the thaperoxides¹⁰. The MMV malaria box is a set of 400 compounds with (sub)micromolar antimalarial activity.

Thaperoxides are derivatives of thapsigargin with an endoperoxide bridge introduced to resemble artemisinin more closely. The MMV OZ box is a blinded set of semi-synthetic artemisinin derivatives. To define assay robustness Z' values were derived²³, for PfATP6 inhibition with CPA Z' = 0.97 ± 0.123, and for SERCA1a with TG Z' = 1.00 ± 0.012.

Hits from the compound screen are summarised in Figure 3a. Initially six hits were identified from the MMV malaria box. Three of these hits gave results that were too variable to take forward. MMV665807 showed the highest reproducible potency against PfATP6 with almost no inhibition of control strains (*K667ΔPDR5::SERCA1a* and *K667ΔPDR5::pUGpd*). Hits from the malaria box were characterised in more detail (Table 3) in *PDR5*-knockout strains and in cultured parasites. Identification of several new chemically unrelated classes of inhibitor of PfATP6 (Figure 3b and Table 3) confirmed a

correlation between inhibitory constants for PfATP6 derived in yeast and anti-parasitic potency (Pearson's $r^2 = 0.7$ ($n = 3$; $p = 0.004$)).

We next investigated if addition of artemisone (the most potent PfATP6 inhibitor and antimalarial) perturbed calcium homeostasis by measuring $[Ca^{2+}]_{free}$ in parasites using a cameleon-Nano biosensor²⁴. Artemisone significantly increased $[Ca^{2+}]_{free}$ in parasites, confirming the relevance of inhibition of PfATP6 (Figure 3c).

Other compounds suggested by the literature were screened but had limited success: Hypericin, BHQ, saikosaponin, spiroindolones, and *tert*-butyl peroxide (Supplementary Figure 1a)^{25–28}. Of these, saikosaponin and spiroindolones inhibited PfATP6 but only at high concentrations ($>100 \mu M$). These results are useful to train selection strategies for future compound screenings identifying PfATP6 inhibitors.

Mutations on drug sensitivity

After expression in *Xenopus* oocytes, sensitivity of SERCA1a to artemisinins was increased by mutating a key amino acid residue (E255L) in the thapsigargin-binding pocket^{29,30}. We confirmed that ^{E255L}SERCA1a was more sensitive to all tested artemisinins, and conversely became five-fold less sensitive to thapsigargin *i.e.* $IC_{50} = 793.6 \pm 247.4$ nM, versus 146.8 ± 43.9 nM for wild-type ($p = 0.011$) (Figure 4a and b respectively).

Fitness cost

Mutations in drug targets can have variable phenotypic manifestations in parasites due to opposing effects of decreased parasite fitness and decreased artemisinin sensitivity as previously proposed^{31,32}. To test this hypothesis, we introduced *in vitro* artemether resistance-conferring mutations S769N and A623E in PfATP6 that have been previously identified in field isolates^{31,33}. These naturally occurring mutations were also supplemented by an L263E mutation that we have previously shown to confer variable resistance in parasites to artemisinins, as it substitutes the malarial amino acid for the mammalian equivalent. Pulcini *et al* (Table 1;¹³) also showed that these mutations confer resistance to artemisinin and its derivatives in the yeast heterologous expression model. ^{A623E}PfATP6 allowed the yeast to grow in all

artemisinins at levels significantly higher than the wild type, except with artesunate. Similarly for ^{S769N}PfATP6 with DHA. Otherwise, all mutations improved yeast growth in the presence of artemisinins.

Mutated PfATP6 sequences were also assayed in yeast for sensitivity to cyclopiazonic acid (CPA), which acts to inhibit SERCA pumps in a different way, both by interaction at different binding sites to those predicted for artemisinins and by hydrophobic interactions, not alkylation³⁴. All mutations (L263E, A623E, ^{S769N}, A623E/^{S769N}) increased sensitivity to CPA, both in parasites¹³ and the yeast heterologous expression assay (Figure 4c). Mean IC₅₀s and S.D. were 11.59 μM ± 0.02 for wild-type, versus 5.21 μM ± 0.03 for L263, 5.86 μM ± 0.04 for A623E, 6.49 μM ± 0.03 for ^{S769N}, and 6.61 μM ± 0.041 for double mutant A623E/^{S769N}. There was a significant difference between the wild type and all mutants (one-way ANOVA multiple comparisons, P value = <0.0001). These findings are consistent with the suggestion that mutations reduce the functionality of PfATP6 as L263E also does in parasites.

Fitness in yeast

To examine the hypothesis that mutations in PfATP6 or SERCA1a decrease fitness in yeast rescue assays, we generated fluorescent reporter strains of yeast (Venus for wild-type PfATP6-expressing yeast and mCherry for the mutant PfATP6-expressing yeast; see image box in Figure 4d). These constructs were used in competition experiments between native and mutated PfATP6 sequences. As ^{S769N}PfATP6 was less sensitive to artemether in parasites in French Guyana, this mutation was selected for detailed investigation³¹. Growth was unaffected by fluorescent markers compared to the non-fluorescent congenic strain (S. Figure 1b), confirming that markers do not cause growth disadvantage.

Across a range of extracellular calcium concentrations (optimal concentration 50 mM), native PfATP6 outcompeted ^{S769N}PfATP6 in growth assays when experiments were begun at ratios of 1:1 or 3:1 (native:mutant strains) and grown until the yeast reached late log phase (18h). Growth levels were comparable when experiments began with 1:3 ratio of native to ^{S769N}PfATP6. When selection with artemether (1μM: approximately yeast IC₈₀) was applied under these conditions, the fitness cost of ^{S769N}PfATP6 became attenuated, and

yeast expressing this mutant had a growth advantage, especially when starting mixtures were in a ratio of 1:3 (native:mutant ratio; Figure 3d). When CPA was used (5 μ M: approximately yeast IC80) instead of artemether as a selective agent, ^{S769N}PfATP6 lost this advantage.

In silico modelling shows the changes in the druggable pockets with different mutations (Figure 5). The X-ray crystal structure of the SERCA in E2 (E309A mutant) was used as a template for building the homology models of PfATP6 and its mutations. The crystal structure shares 48% of sequence identity with pfATP6 and it covers amino acids from 5 through 1217. The predicted binding pocket for the modeled PfATP6, ^{L263E}PfATP6, ^{A623E}PfATP6, and ^{S769N}PfATP6 has volume of 624.411, 922.372, 1746.135, and 1048.841 Å³ respectively. The mutations, even the distant ones, led to changes in volume of the binding cavity adjacent to Leu263.

Discussion

More than three decades ago we suggested that parasite integral membrane transport proteins may be useful drug targets^{35,36}. In the course of investigating various families of transport proteins we first isolated, functionally characterised in *Xenopus* oocytes, and genetically validated the parasite's hexose transporter, PfHT, as a new drug target³⁷. Co-crystallisation of PfHT with the selective inhibitor we characterised has confirmed that structure-based design of inhibitors against integral membrane proteins of *P. falciparum* is feasible³⁸. Our early work also pointed to a family of P-type cation ATPases as promising for further study as drug targets. PfATP4 was characterised as an atypical cation ATPase initially proposed to be a calcium ATPase³⁹ and then was found to export sodium from the intraerythrocytic parasite⁴⁰. These studies are particularly interesting because PfATP4 is now an established drug target for several novel classes of antimalarial, including the spiroindolones that have reached clinical studies in development⁴¹. PfATP4 also has mutations that can confer resistance to inhibitors and drugs⁴².

PfATP6 has also been confirmed as a validated drug target by genetic studies¹³. Artemisinins were first shown to inhibit PfATP6 after expression in *Xenopus* oocytes, and to interact with PfATP6 in parasites⁹. These observations led to the hypothesis that PfATP6 was the key target of artemisinins' antiparasitic activity. Since then, artemisinins have displayed promiscuity in their targeting of parasite proteins by alkylating them^{18,19}. This mechanism may explain several features of assays with artemisinins. For example, parasites display both higher variances and inconsistencies in IC₅₀ responses to artemisinins when bearing mutations in PfATP6¹¹, predicted to reduce their susceptibility to artemisinins. The presence of more than one important target for artemisinins' antimalarial activity (64-123 artemisinin-labelled proteins were identified, although not all would be plausible targets) may explain some variability in IC₅₀ results because 'secondary' or 'tertiary' targets may become more important if a 'primary' target becomes less susceptible. This suggestion is reassuring for the risk of developing artemisinin resistance, because multiple targets may maintain parasite sensitivity to this class of antimalarial. Consistent with this suggestion of multiple targets, there may even be more than one binding site within a single protein target.

Different artemisinin derivatives behave differently against mutant PfATP6 *in vitro*. Adding to this complexity in interpreting susceptibilities of parasites with mutations in PfATP6 is their fitness cost, suggested in cultured parasites for those bearing the S769N PfATP6, and now demonstrated in yeast models³². It also explains why it may have proved difficult to establish parasites with some PfATP6 mutations in cultures *ex vivo* for longer term further study. Studying the effects of mutations in PfATP6 observed in field isolates, and in laboratory models of parasites and after heterologous expression are consistent with these mutations being able to exert remote influence on the properties of drug binding regions (Figure 5). Expression in yeast suggests that mutations in the cytosolic domains of PfATP6 (S769N and A623E, for example) can also exact fitness costs, and these costs can may be ameliorated under drug selection pressure with some artemisinin derivatives.

To address differences in results of assays of PfATP6 in *Xenopus* oocytes reported by different groups, we developed a robust yeast whole cell assay to study artemisinins, to compare results to mammalian SERCA and to allow screening of inhibitors. Earlier immunolocalization experiments demonstrated PfATP6 is expressed in internal membrane structures in yeast¹³. The alkylation of PfATP6 by an artemisinin derivative when expressed in yeast (as in parasites), together with growth rescue of inhibition by artemisinins in this model confirms our earlier observations made in *Xenopus* oocytes on inhibition of PfATP6 and the effects of mutations^{9,29}.

To confirm that mammalian SERCA1a can be made more susceptible to artemisinins, we also mutated its sequence as before (E255L-SERCA1a) and again demonstrated increased susceptibility to artemisinins²⁹ (Fig 4a). Interestingly, this sequence is less susceptible to thapsigargin (Fig 4b). These observations confirm that artemisinins target PfATP6, and that this inhibition can result in increases in free intraparasitic calcium concentrations when challenged with a potent artemisinin (Fig 3c). These observations also highlight how methodologies used to assay function in different expression systems may give apparently inconsistent results. *In vitro* activity assays also demonstrate this point, as no compound tested showed any inhibition of purified PfATP6 despite apparent inhibition of purified SERCA1a by CPA in parallel

experiments, suggesting PfATP6 may not function in a representative way in *in vitro* assays (S. Figure 1c and 1d).

Treatment failure with artemisinin combination therapy (ACT) emerged in the early 1990s and is currently localised to the Greater Mekong region^{43,44}. Fortunately, appropriately selected ACTs continue to be effective in treating *P. falciparum* infections in this region when the partner drug is efficacious, and case numbers continue to fall⁴⁵.

Using PfATP6 as a ‘model’ target allowed assessment of the importance of other targets, because even with mutations that are predicted to decrease sensitivity of PfATP6, assays in parasites bearing such mutations suggested more variable IC₅₀ results, both in field and laboratory generated strains. Fitness cost in the yeast model is ameliorated when these PfATP6 mutant strains are exposed to artemisinin derivatives, perhaps explaining why some parasites strains have been unstable in the laboratory when grown without drug selection pressure³². Future fitness cost assays could be carried out with yeast that have fluorescent markers incorporated into chromosomal DNA, rather than in a vector, to provide a simpler ‘plug-and-play’ platform.

To address problems of drug resistance in parasites, we exploited the yeast screening model, as it is eukaryotic, easily genetically manipulated, and knock-out libraries are freely available (e.g. through EUROSCARF, Germany). One limitation is that any proposed target needs to have an orthologue in yeast, so targeting mechanisms that relate to parasite-specific properties such as red cell invasion might be difficult. Also, anti-parasitic drugs are often stage-specific (which needs to be taken into account when choosing targets, since yeast do not have comparable life cycles). Yeast can respire aerobically or anaerobically, depending upon the carbon source in the medium, further distinguishing it from parasites and an inhibitory effect on yeast aerobic respiration apparatus is only apparent when the carbon source ensures yeast rely on mitochondrial respiration, rather than glycolysis⁴⁶.

Inhibitory constants in yeast screens were correlated with those in parasite assays. Differences in their magnitude (e.g. artemisinin = 17 nM in parasites vs. 1.8 µM in yeast) could be explained by several factors. A requirement for activation of artemisinins by haem is a possibility because haem was not included in the yeast growth assays. Haem abolishes artemisinins’ ability to

inhibit yeast growth in fermentable media⁴⁶. Also yeast has many efflux pumps that lower its sensitivity to inhibitors, and *K667ΔPDR5::HIS*[PfATP6] yeast was 4-11 times more sensitive to artemisinin than the *K667*[PfATP6] strain. We did not knock out other potential efflux pumps, of which more than a dozen remain. This mechanism and its relevance to parasites is amenable to further study by introduction, for example, of the *P. falciparum* efflux pump Pfmdr1. In conclusion, several independent experimental findings are consistent with the hypothesis that artemisinins target PfATP6. PfATP6 can be inhibited by a variety of unrelated compounds after heterologous expression in a yeast screening system, demonstrating its potential as a drug target, and potencies correlate with parasite killing. Mutations in PfATP6 can incur fitness costs. Because artemisinins interact with multiple targets including PfATP6, our findings suggest that a decreased sensitivity to artemisinins (assayed in ring stages) may depend on a global response of the parasite by selection to delay its developmental cycle. They also suggest that the term ‘artemisinin resistance’ may be best reserved for parasites that have been selected to demonstrate increased IC₅₀ values to artemisinins in conventional *in vitro* assays, rather than those focused on decreased ring stage sensitivity.

Materials and Methods

Reagents

All reagents were purchased from Sigma-Aldrich except for thaperoxides (made by M. Avery). The OZ derivatives and the malaria box compounds were kindly donated by the Medicines for Malaria Venture²². Reference strain and K667 strain were from EUROSCARF (Germany) and the plasmid containing SERCA1a was kindly donated by Prof. Ghislain (Université Catholique de Louvain, Louvain-la-Neuve, Belgium). Plasmids with fluorescent markers were kindly donated by Dr. Elizabeth Bilslan²⁰. All kits were purchased from Qiagen. All mass spectrometry was performed by Dr. Jigang Wang. Antibodies were purchased from Abcam.

Yeast strains

Name	Strain	Genotype
Reference strain	BY4741	Mat a; <i>his3Δ1</i> ; <i>leu2Δ0</i> ; <i>met15Δ0</i> ; <i>ura3Δ0</i>
K667	W-303	Mat a; <i>ade2Δ1</i> , <i>can1Δ100</i> , <i>his3Δ11</i> , 15 <i>leu2Δ3</i> , 11, 2, <i>trp1Δ1</i> , <i>ura3Δ1</i> , <i>cnb1::LEU1</i> <i>pmc1::TRP1</i> <i>vcx1Δ</i>

Transformations

Yeast transformations were performed using the method described by Gietz and Schiestl⁴⁷ and transformants were selected by an uracil auxotrophic marker. Transformations were confirmed by colony PCR. Both K667 and *K667Δpdr5::HIS* were transformed with the following plasmids: pUGpd plasmid as a vector-only control (derived from pRS316⁴⁸); br434 plasmid (derived from pRS316,⁴⁹) containing the SERCA1a coding region from rabbit skeletal fast-twitch muscle (*pbr434-SERCA1a*); and pUGpd containing the yeast-optimised coding region of PfATP6 from *Plasmodium falciparum* (*pUGpd-PfATP6*). Site-directed mutagenesis was performed on the SERCA1a coding region to produce the mutation E255L in the protein. Mutations were also introduced into

the PfATP6 coding region to produce mutations L263E, A623E, S769N, and the double mutation A623E/S769N¹³.

Homologous recombination

To knock out the *PDR5* gene from the K667 strain of yeast, the auxotrophic marker HISMX was amplified using the following primers²⁰:

5'- AGACCCCTTTTAAGTTTTTCGTATCCGCTCGTTTCGAAAGACTTTAGAATGGCAGAACCAGCC -3'

5'- TGTTTATTAATAAAAGTCCATCTTGTAAGTTTCTTTCTTAACCATACCTCAGATCAAAA -3'

where the underlined region is homologous with HISMX. PCR products were used to transform the K667 strain as above. Knockouts were selected by their ability to grow on histidine-depleted selective medium. Recombination was confirmed with colony PCR.

Immunocytochemistry

Immunocytochemistry was performed as described in Kilmartin and Adams⁵⁰. Briefly, yeast were grown to an optical density equivalent to log phase and were prepared for immunostaining by removing the cell wall. The cell suspension was spotted on polylysine-coated microscope slides and dried, fixed, and permeabilised. Primary antibody (mouse anti-SERCA1a, Abcam) was added and incubated overnight at +4 °C. Secondary antibody (goat anti-mouse Texas Red-tagged) was added and incubated for at least two hours. The slides were stained with 5 µM DiI₆OC for 20 minutes to stain endoplasmic reticulum. Antifade mounting medium plus DAPI was added before sealing the slides. Yeast were visualised with a Zeiss Confocal LSM 510 microscope.

Immunofluorescence with *P. falciparum* parasites was performed as in Pulcini *et al.*¹³, using paraformaldehyde/glutaraldehyde fixation method. Parasites were labelled as in Wang *et al.*¹⁸, using 500 nM of DHA-biotin probe. Parasites were visualised with a Zeiss Confocal LSM 510 microscope.

Site-directed mutagenesis

The E255L mutation was introduced into SERCA1a using the following primers:

5'- GCCGCTGCAGCAGAAGCTGGATTTATTCGGGGAGCAG -3' Forward

5'- CTGCTCCCCGAATAAATCCAGCTTCTGCTGCAGCGGC -3' Reverse

Site-directed mutagenesis was performed using the Agilent Quikchange Lightning site-directed mutagenesis kit following manufacturer's instructions. Mutants were screened by Sanger sequencing (Eurofins, UK).

Whole-cell screening assay

The screening assay used here was developed from the protocol used in Pulcini *et al.*,¹³. A single colony of the yeast strain to be screened was picked and grown in 5 ml of selective medium until stationary phase was reached. The culture was diluted 100-fold in ampicillin-supplemented YPD medium to an O.D._{620nm} equivalent to that of lag phase. YPD was supplemented with an appropriate concentration of calcium, depending upon the transformed strain. The optimum calcium concentration for the PfATP6-expressing strain was 22 mM, and 100 mM for the SERCA1a-expressing strain. The optimum calcium concentration was periodically monitored and, if necessary, adjusted using a calcium concentration range of 10 to 30 mM. A final volume of 200 µl of the yeast culture was added to each well of a 96-well plate, with 5 technical replicates included per inhibitor. All inhibitors were dissolved in DMSO unless otherwise stated. Stock solutions of each inhibitor were diluted 100-fold in each well to give the desired final concentration. Where IC₅₀s were being determined, inhibitors were two-fold titrated from stock solution. The 96-well plates were incubated at 30°C for 42 hours. The yeast growth was estimated from the absorbance at 620 nm in a Tecan plate reader. Growth was normalised with the no-drug control to present data as % growth.

The data collected were analysed using GraphPad Prism 9.0, (GraphPad Software, CA, U.S.A).

***In vitro* parasite assays**

Inhibitor IC₅₀s were calculated in parasite assays following the protocol described in Desjardins *et al.*⁵¹. Briefly, cultures were synchronised to ring stage by sorbitol lysis, using 5% sorbitol solution. The parasites were diluted to a final parasitaemia of 1%. Hypoxanthine-free medium was added to give a haematocrit of 4%. A two-fold dilution series of the inhibitors in hypoxanthine-free medium was prepared. 100 µl of each inhibitor concentration was seeded in a 96-well plate, with five technical replicates of each included. Two no-

inhibitor controls *i.e.* hypoxanthine-free medium only, were included. Plates were incubated at 37°C in 5% CO₂ for 24 h. After 24 h [³H]hypoxanthine was added to each well to a final concentration of 0.5 µCi/well and incubated for a further 24 h. Plates were then freeze-thawed to lyse the cells, and the [³H]hypoxanthine uptake was measured in a Beckman scintillation counter. Parasite calcium homeostasis was measured as described in Pandey *et al.*²⁴, using artemisinin derivative artemisone.

Fitness cost assays

Fitness cost assays were performed in yeast by transforming the strain K667[PfATP6]^{wt} with yEpGAP-Venus, and the strain K667[PfATP6]^{769N} were transformed with yEpGAP-Cherry. Both vectors were kindly donated by Dr Bilisland²⁰. Growth of the transformed and untransformed strains were compared using growth curves, performed as in Moore *et al.*⁴⁶. Standard curves were generated for each strain by measuring fluorescence at each optical density in a two-fold dilution series of the yeast. The yeast were diluted to an optical density equivalent to log phase and co-inoculated at an equal starting optical density. Yeast were incubated at 30°C for 24 hours at which point the yeast were in late log phase. The fluorescence was then measured for both fluorophores and growth was estimated by calculating the optical density using the standard curve. The optical density was also measured. The experiments were repeated in the presence of drug pressure using 1 µM Artemether or 5 µM CPA (*i.e.* approximate IC₁₀).

Standard curves calculated from optical density measurements and fluorescent measurements of titrations of each fluorescent strain of yeast were used to relate relative fluorescence to the equivalent optical density, such that each strain in a 1:1 mixture should have equivalent relative fluorescence and make up 50% each of the total optical density.

***In silico* modelling**

Prime was used to construct and refine the 3D models of wild-type PfATP6, L263E PfATP6, A623E PfATP6, and S769N PfATP6 (Template: PDB accession code 5ZMV). The basic local alignment search tool of homology search was used to identify the highest homologous protein structures from the PDB repository

(<http://www.rcsb.org>) by using position-specific iterative basic local alignment search tool, NCBI NR database, BLOSUM62 similarity matrix, gap opening cost of 11, gap extension penalty of 1, inclusion threshold of 0.005 and three iterations. The secondary structure prediction was then established by SSPro, followed by sequence alignment with ClustalW. Knowledge-based 3D model builder was used to construct the models for each target sequence. Loops were refined by using VSGB solvation model and extended serial loop sampling. Side chains were then re-predicted for the refined loops, and the final 3D models was energy minimized using OPLSe force field and VSGB solvation model. The protein structure quality was checked in the Schrödinger suite. The binding pockets of PfATP6 and all mutations were predicted using f-pocket to identify the most plausible cavities close to L/E263.

Microsome preparation

Protein-enriched microsomes were prepared as described in Nakanishi *et al.*⁵², and Hwang *et al.*⁵³. Briefly, yeast was grown in 1L of YPD medium until an O.D._{600nm} of 1.5-2.0 was reached. Yeast were pelleted and resuspended in 50 ml per 500ml culture of buffer 1 (0.1M Tris-HCl, pH 9.4, 50 mM 2-mercaptoethanol, 0.1 M glucose). After shaking at 30°C for 10 min, the yeast were pelleted and resuspended in 50 ml per 500 ml original culture of buffer 2 (0.9 M sorbitol, 0.1M glucose, 50 mM Tris-Mes, pH 7.6, 5 mM DTT, 0.5x SD medium, 0.05% w/v Zymolase 20T) and incubated at 30°C for 1-2 h, with gentle shaking. The yeast were pelleted and washed with 30 ml per original culture of 1 M sorbitol. The yeast were pelleted and resuspended in 20 ml per original culture of buffer 3 (50 mM Tris-Mes, pH 7.6, 1.1 M glycerol, 1.5% w/v PVP 40,000, 5 mM EGTA, 1 mM DTT, 0.2% w/v BSA, 1 mM PMSF, 1x protease inhibitor) on ice and homogenised. The homogenate was pelleted and the supernatant was transferred to ultracentrifuge tubes. The pellet was resuspended in buffer 3 and pelleted again. This second supernatant was pooled with the previous and centrifuged at 150,000 g for 45 min at 4°C. The pellet was resuspended in 1-2 ml buffer 5 (5 mM Tris-Mes, pH 7.6, 0.3 M sorbitol, 1 mM DTT, 1 mM PMSF, and 1x protease inhibitor) and aliquoted for single use before freezing in liquid N₂.

Mass spectrometry and activity assays

Both whole yeast and microsomes were prepared for mass spectrometry analysis by adding 500 nM of probe to 200 μ L (~0.6 mg protein) of yeast microsomes preparation, or 10 μ M probe to 50 – 100 ml yeast culture at O.D. 1.0 - 1.5 (~35 - 70 mg total protein), and incubated for 4 hr at 30°C. For competition studies, x25 artesunate was added and incubated for 30 minutes, before adding the probe and incubating for 4 hr, at 30°C. Samples were then acetone-precipitated by adding 4 volumes of -20°C acetone:water (4:1) to the yeast pellet or microsomal pellet and incubating for 2 hours to overnight at -20°C. Then the samples were pelleted at 13,000 – 16,000 $\times g$ for 10 minutes at 0 - 4°C and washed twice with -20°C acetone:water solution. After a final centrifugation pellets were dried in a freeze-drier for one hour. Subsequent pull-downs and LC-MS/MS was performed as described in Wang *et al.*¹⁸.

Activity assays were performed as in Longland *et al.*⁵⁴ and LeBel *et al.*⁵⁵, except the reactions were incubated at 30°C instead of 37°C. Briefly, microsomes were diluted to 75 μ g/ml, with free calcium at approximately 1 μ M, in 2 ml assay buffer (45 mM HEPES/KOH pH 7.2, 6 mM $MgCl_2$, 2 mM NaN_3 , 250 mM sucrose, 12.5 μ g/ml A23187, 2 mM EGTA, $\pm$ 2mM $CaCl_2$) and incubated for 10 minutes at 30°C in presence/absence of inhibitor (10-100 μ M). Then 5.8 mM ATP was added and incubated for a further 15 minutes at 30°C. The reaction is stopped with 0.5 ml 6.5% TCA, on ice, and centrifuged at 4°C for 10 minutes (16,000 $\times g$). 0.5 ml of the supernatant was added to 1.5 ml of copper acetate buffer (0.25% copper sulphate pentahydrate, 4.6% sodium acetate trihydrate, dissolved in 2M acetic acid pH 4.0) and mixed by vortexing, before addition of 0.25 ml of 5% ammonium molybdate, followed by 0.25 ml METOL buffer (2% p-methyl-aminophenol sulphate, 5% sodium sulphite). Samples were incubated for 10 minutes and absorbance measured at 870 nm in spectrophotometer. Pi standard was 0.4387 g/100 ml KH_2PO_4 .

Pull-down assays

A 0.3 mg aliquot of PfATP6-enriched membrane vesicles, as well as an aliquot of SERCA1a and vector-only membrane vesicles, were thawed on ice. Half of

each aliquot (0.15 mg) was preincubated with 12.5 μ M artesunate at 30°C for 30 minutes. Then all samples had 500 nM DHA-biotin probe added (NewChem Technologies Ltd) and incubated at 30°C for 4 hours. The samples were then pulled down using Dynabeads following manufacturers' instructions. 2 mg of beads were used per sample. Beads and samples were boiled for 5 minutes in 0.1% SDS to separate the beads from the proteins and supernatants were run on a polyacrylamide gel. Western blots were performed according to the Thermo Fisher NuPage western blot protocol, using 10% Bis-Tris gels (Thermo Fisher, UK) with mouse anti-SERCA1a primary antibody or goat anti-PfATP6 antibody (1/1000), and LiCor donkey anti-mouse or donkey anti-goat fluorescent-tagged secondary antibodies (1/10,000). Blots were analysed using the Odyssey scanner system. Densitometry was performed using Image Studio software.

Statistics

T-tests and one-way ANOVA were performed using Graphpad Prism software, unpaired and two-tailed. * = $p < 0.05$, ** = $p < 0.005$, *** = $p < 0.0005$ except where stated otherwise.

Bibliography

1. WHO. World malaria report 2019. <https://www.who.int/publications/i/item/9789241565721>.
2. Global Malaria Programme. <https://www.who.int/teams/global-malaria-programme/guidelines-for-malaria> (2021).
3. Wang, J. *et al.* Suboptimal dosing triggers artemisinin partner drug resistance. *Lancet Infect. Dis.* **19**, 1167–1168 (2019).
4. Wang, J. *et al.* A Temporizing Solution to “Artemisinin Resistance”. <https://doi.org/10.1056/NEJMp1901233> **380**, 2087–2089 (2019).
5. Krishna, S. & Kremsner, P. G. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. *Trends Parasitol.* **29**, 313–317 (2013).
6. Gil, J. P. & Krishna, S. pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin

- 621 combination therapies. *Expert Rev. Anti. Infect. Ther.* **15**, 527–543
622 (2017).
- 623 7. Augustin, Y., Staines, H. M. & Krishna, S. Artemisinins as a novel anti-
624 cancer therapy: Targeting a global cancer pandemic through drug
625 repurposing. *Pharmacol. Ther.* **216**, (2020).
- 626 8. Krishna, S. *et al.* Repurposing Antimalarials to Tackle the COVID-19
627 Pandemic. *Trends Parasitol.* **37**, 8–11 (2021).
- 628 9. Eckstein-Ludwig, U. *et al.* Artemisinins target the SERCA of
629 Plasmodium falciparum. *Nature* **424**, 957–961 (2003).
- 630 10. Sun, L. *et al.* Design, synthesis, and development of novel guaianolide-
631 endoperoxides as potential antimalarial agents. *J. Med. Chem.* **53**,
632 7864–7868 (2010).
- 633 11. Valderramos, S. G., Scafield, D., Uhlemann, A. C., Fidock, D. A. &
634 Krishna, S. Investigations into the role of the Plasmodium falciparum
635 SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
636 *Antimicrob. Agents Chemother.* **54**, 3842–3852 (2010).
- 637 12. Krishna, S., Pulcini, S., Moore, C. M., Teo, B. H.-Y. & Staines, H. M.
638 Pumped up: Reflections on PfATP6 as the target for artemisinins.
639 *Trends Pharmacol. Sci.* **35**, (2014).
- 640 13. Pulcini, S. *et al.* Expression in Yeast Links Field Polymorphisms in
641 PfATP6 to in Vitro Artemisinin Resistance and Identifies New Inhibitor
642 Classes. *J. Infect. Dis.* **208**, 468–478 (2013).
- 643 14. Toovey, S., Bustamante, L. Y., Uhlemann, A.-C., East, J. M. & Krishna,
644 S. Effect of Artemisinins and Amino Alcohol Partner Antimalarials on
645 Mammalian Sarcoendoplasmic Reticulum Calcium Adenosine
646 Triphosphatase Activity. *Basic Clin. Pharmacol. Toxicol.* **103**, 209–213
647 (2008).
- 648 15. Lu, M., Sun, L., Zhou, J., Zhao, Y. & Deng, X. Dihydroartemisinin-
649 Induced Apoptosis is Associated with Inhibition of Sarco/Endoplasmic
650 Reticulum Calcium ATPase Activity in Colorectal Cancer. *Cell Biochem.*
651 *Biophys.* **2015 731 73**, 137–145 (2015).
- 652 16. Cardi, D. *et al.* Purified E255L mutant SERCA1a and purified PfATP6
653 are sensitive to SERCA-type inhibitors but insensitive to artemisinins. *J.*
654 *Biol. Chem.* **285**, 26406–26416 (2010).

17. Yang, Y. Z., Little, B. & Meshnick, S. R. Alkylation of proteins by artemisinin. Effects of heme, pH, and drug structure. *Biochem. Pharmacol.* **48**, 569–573 (1994).
18. Wang, J. *et al.* Haem-activated promiscuous targeting of artemisinin in *Plasmodium falciparum*. *Nat. Commun.* **6**, (2015).
19. Ismail, H. M. *et al.* Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites *Plasmodium falciparum* 3D7. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 2080–2085 (2016).
20. Bilsland, E. *et al.* Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds. *Open Biol.* **3**, (2013).
21. Wang, J. *et al.* Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticorectal Cancer Activity. *ACS Cent. Sci.* **3**, 743–750 (2017).
22. Spangenberg, T. *et al.* The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases. *PLoS One* **8**, e62906 (2013).
23. Zhang, J.-H., Chung, T. D. Y. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays: <http://dx.doi.org/10.1177/108705719900400206> **4**, 67–73 (1999).
24. Pandey, K. *et al.* Ca²⁺ monitoring in *Plasmodium falciparum* using the yellow cameleon-Nano biosensor. *Sci. Rep.* **6**, (2016).
25. Eriksson, E. S. & Eriksson, L. A. Identifying the sarco(endo)plasmic reticulum Ca²⁺ ATPase (SERCA) as a potential target for hypericin--a theoretical study. *Phys. Chem. Chem. Phys.* **14**, 12637–12646 (2012).
26. Kempton, R. J., Kidd-Kautz, T. A., Laurenceau, S. & Paula, S. Heck- and Suzuki-coupling approaches to novel hydroquinone inhibitors of calcium ATPase. *Beilstein J. Org. Chem.* **15**, 971–975 (2019).
27. Wong, V. K. *et al.* Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells. *Cell Death Dis.* **4**, (2013).
28. Kamei, Y., Koushi, M., Aoyama, Y. & Asakai, R. The yeast

- mitochondrial permeability transition is regulated by reactive oxygen species, endogenous Ca²⁺ and Cpr3, mediating cell death. *Biochim. Biophys. acta. Bioenerg.* **1859**, 1313–1326 (2018).
29. Uhlemann, A.-C. *et al.* A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. *Nat. Struct. Mol. Biol.* **12**, 628–629 (2005).
30. Uhlemann, A.-C. *et al.* Erratum: A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. *Nat. Struct. Mol. Biol.* **2012** *192* **19**, 264–264 (2012).
31. Jambou, R. *et al.* Resistance of *Plasmodium falciparum* field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. *Lancet* **366**, 1960–1963 (2005).
32. Legrand, E., B, V., JB, M., O, M.-P. & P, E. In vitro monitoring of *Plasmodium falciparum* drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. *Antimicrob. Agents Chemother.* **52**, 288–298 (2008).
33. Pillai, D. R. *et al.* Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with *Plasmodium falciparum* infections. *Malar. J.* **11**, 131 (2012).
34. Bleeker, N. P., Cornea, R. L., Thomas, D. D. & Xing, C. A Novel SERCA Inhibitor Demonstrates Synergy with Classic SERCA Inhibitors and Targets Multidrug-Resistant AML. *Mol. Pharm.* **10**, 4358 (2013).
35. Krishna, S. *et al.* A family of cation ATPase-like molecules from *Plasmodium falciparum*. *J. Cell Biol.* **120**, 385–398 (1993).
36. Krishna, S. & Robson, K. J. *Biochemical Protozoology*. (Taylor and Francis Inc., 1991).
37. Joet, T., Eckstein-Ludwig, U., Morin, C. & Krishna, S. Validation of the hexose transporter of *Plasmodium falciparum* as a novel drug target. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 7476–7479 (2003).
38. Huang, J. *et al.* Orthosteric-allosteric dual inhibitors of PfHT1 as selective antimalarial agents. *Proc. Natl. Acad. Sci. U. S. A.* **118**, (2021).
39. Das, S. *et al.* Na⁺ Influx Induced by New Antimalarials Causes Rapid

- 723 Alterations in the Cholesterol Content and Morphology of Plasmodium
724 falciparum. *PLOS Pathog.* **12**, e1005647 (2016).
- 725 40. Rosling, J. E. O., Ridgway, M. C., Summers, R. L., Kirk, K. & Lehane, A.
726 M. Biochemical characterization and chemical inhibition of PfATP4-
727 associated Na⁺-ATPase activity in Plasmodium falciparum
728 membranes. *J. Biol. Chem.* **293**, 13327–13337 (2018).
- 729 41. Spillman, N. J. & Kirk, K. The malaria parasite cation ATPase PfATP4
730 and its role in the mechanism of action of a new arsenal of antimalarial
731 drugs. *Int. J. Parasitol. Drugs Drug Resist.* **5**, 149 (2015).
- 732 42. Dennis, A. S. M., Rosling, J. E. O., Lehane, A. M. & Kirk, K. Diverse
733 antimalarials from whole-cell phenotypic screens disrupt malaria
734 parasite ion and volume homeostasis. *Sci. Rep.* **8**, (2018).
- 735 43. Das, S. *et al.* Artemisinin combination therapy fails even in the absence
736 of Plasmodium falciparum kelch13 gene polymorphism in Central India.
737 *Sci. Reports 2021 111* **11**, 1–12 (2021).
- 738 44. Noedl, H. *et al.* Evidence of Artemisinin-Resistant Malaria in Western
739 Cambodia. <http://dx.doi.org/10.1056/NEJMc0805011> **359**, 2619–2620
740 (2009).
- 741 45. Wang, J. *et al.* Triple artemisinin-based combination therapies for
742 malaria: proceed with caution. *Lancet* **396**, 1976 (2020).
- 743 46. Moore, C. M., Hoey, E. M., Trudgett, A. & Timson, D. J. Artemisinins act
744 through at least two targets in a yeast model. *FEMS Yeast Res.* **11**,
745 (2011).
- 746 47. Gietz, R. D. & Schiestl, R. H. Quick and easy yeast transformation using
747 the LiAc/SS carrier DNA/PEG method. *Nat. Protoc.* **2**, 35–37 (2007).
- 748 48. Zhao, J. *et al.* Functional studies of split Arabidopsis Ca²⁺/H⁺
749 exchangers. *J. Biol. Chem.* **284**, 34075–34083 (2009).
- 750 49. Dürr, G. *et al.* The medial-Golgi ion pump Pmr1 supplies the yeast
751 secretory pathway with Ca²⁺ and Mn²⁺ required for glycosylation,
752 sorting, and endoplasmic reticulum-Associated protein degradation.
753 *Mol. Biol. Cell* **9**, 1149–1162 (1998).
- 754 50. Kilmartin, J. V. & Adams, A. E. M. Structural rearrangements of tubulin
755 and actin during the cell cycle of the yeast *Saccharomyces*. *J. Cell Biol.*
756 **98**, 922–933 (1984).

51. Desjardins, R. E., Canfield, C. J., Haynes, J. D. & Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. *Antimicrob. Agents Chemother.* **16**, 710 (1979).
52. Nakanishi, H. *et al.* Hut1 proteins identified in *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe* are functional homologues involved in the protein-folding process at the endoplasmic reticulum. *Yeast* **18**, 543–554 (2001).
53. Hwang, I., Harper, J. F., Liang, F. & Sze, H. Calmodulin activation of an endoplasmic reticulum-located calcium pump involves an interaction with the N-terminal autoinhibitory domain. *Plant Physiol.* **122**, 157–167 (2000).
54. Longland, C. L. *et al.* Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormone-mastoparan constructs. *Cell Calcium* **24**, 27–34 (1998).
55. LeBel, D., Poirier, G. G. & Beaudoin, A. R. A convenient method for the ATPase assay. *Anal. Biochem.* **85**, 86–89 (1978).

Acknowledgements

We gratefully acknowledge support from the European Community's Seventh Framework Programme (FP7/2007-2013); NanoMal under grant agreement number 304948 to S. Krishna and H. Staines. H. Staines is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George's University of London. S. Krishna is co-chair of the Guidelines Development Group for Antimalarials of the World Health Organisation. Views here are personal and do not represent those of the Committee. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

787 **Abbreviations**

788	PfATP6 <i>Plasmodium falciparum</i> ATPase 6
789	ACT Artemisinin Combination Therapy
790	SERCA1a Sarco/Endoplasmic Reticulum Calcium ATPase 1a
791	DHA Dihydroartemisinin
792	PMC1 Calcium ATPase in vacuole
793	PMR1 Calcium ATPase in golgi
794	CPA cyclopiazonic acid
795	DFO Desferrioxamine
796	MMV Medicines for Malaria Venture
797	BHQ Benzohydroquinone
798	ART Artemisinin
799	ATR Artemether
800	ONE Artemisone
801	AS Artesunate
802	TG Thapsigargin
803	PfHT <i>Plasmodium falciparum</i> Hexose Transporter
804	PfATP4 <i>Plasmodium falciparum</i> ATPase 4
805	PfMDR1 <i>Plasmodium falciparum</i> MultiDrug Resistance transporter 1
806	DTT Dithiothreitol
807	BSA Bovine Serum Albumin
808	PMSF Phenylmethylsulfonyl Fluoride
809	O.D. Optical Density
810	TCA Trichloroacetic Acid
811	

Figures

Figure 1. Yeast expression and optimisation. **A.** Immunofluorescence of SERCA1a. Yeast (top left) stained with primary SERCA1a antibody and Texas Red-tagged goat anti-mouse secondary antibody (bottom-left), as well as Di₆OC stain for ER (top right), and DAPI (bottom right merge). **B.** Growth of K667[SERCA1a] strain (white), reference strain BY4741 (black), and K667[SERCA1a] treated with 1 µM thapsigargin (TG) (striped) in an extracellular calcium concentration range. Error bars are S.D. of the means of 5 technical replicates. **C.** K667[SERCA1a] strain (white) and K667[PfATP6] strain (shaded) treated with 10 µM of artemisinin (ART), dihydroartemisinin (DHA), artemisone (ONE), and cyclopiazonic acid (CPA). Error bars are S.E.M. of 3 biological means of 5 technical replicates. (** = $p < 0.0075$, * = $p < 0.05$) **D.** Dose response curves of K667[SERCA1a] strain (solid line black square) and K667Δpdr5[SERCA1a] (dotted line open circles) to TG.

Figure 2. Artemisinins' interaction with PfATP6. A. DHA-biotin probe structure. **B.** Western blots of PfATP6-enriched microsome pull-downs untreated (1), pre-incubated with 200 μ M haem (2), and pre-incubated with haem and 200 μ M DFO (3). Fold change refers to band intensity relative to PfATP6 (1). **C.** Western blots of PfATP6- and SERCA1a- enriched microsome pull-downs pre-incubated with 'cold' artesunate before performing pull-downs with DHA-biotin. **D.** Immunofluorescence assay with *P. falciparum* parasites. Trophozoite-stage parasites were pre-incubated with DHA-biotin before staining with TRITC-tagged anti-biotin antibody (red, top panel), and by DAPI (blue, middle panel). Merge in bottom panel.

Figure 3. Inhibitor screens on whole yeast and parasites. A. All compounds were screened against K667 Δ pdr5[PfATP6] and two control strains K667 Δ pdr5[SERCA1a] and K667 Δ pdr5[pUG]. K667 Δ pdr5[PfATP6] positive control is DHA and K667 Δ pdr5[SERCA1a] is TG. For each class of inhibitor a representative structure is shown. **B.** The correlation between the yeast assay-derived IC₅₀ values (μ M) and the *in vitro* parasite assay-derived IC₅₀ values (μ M) for inhibitors had a *r* value of 0.7 (Pearson analysis *P* = 0.004). Artemisinins are in black. MMV compounds are in green, magenta, red/orange and purple. Circles denote parent compounds and squares derivatives. CPA is represented by the blue circle. Error bars are $\pm$ S.E.M. **C.** Parasites treated with artemisone had perturbed calcium transport. Arrow indicates addition of artemisone. Geometric means were derived from 3 biological replicates. *P* = 0.016 (one way ANOVA uncorrected Fisher's LSD).

Figure 4. Effect of SNPs on artemisinin sensitivity. **A.** K667 Δ pdr5[SERCA1a]^{E255} (white) and K667 Δ pdr5[SERCA1a]^{255L} (black) were treated with 100 μ M artemisinin (ART), artesunate (AS), dihydroartemisinin (DHA), artemisone (ONE) and artemether (ATR). *** = $P < 0.0001$ **B.** Dose response curve of K667 Δ pdr5[SERCA1a]^{255L} (dotted) and K667 Δ pdr5[SERCA1a]^{E255} (solid) to thapsigargin (TG). NB: IC₅₀ for K667 Δ pdr5[SERCA1a]^{E255} same as that for Figure 1d, as the assays were performed together. **C.** Dose response curves to CPA for K667[PfATP6] wild type (black circles) versus strains expressing PfATP6 with resistance-conferring SNPs S769N (blue triangle), L263E (green square), A623E (red triangle), and A623E/S769N (magenta diamond). **D.** Fitness cost of K667 Δ pdr5[mCherry][PfATP6]^{769N} compared to the wild type K667 Δ pdr5[Venus][PfATP6]^{S769}, with and without drug pressure from 1 μ M artemether (ATR), or 5 μ M CPA. Extracellular calcium concentration 50 mM. Fitness cost presented as change in growth between wild type and mutant after co-incubation. Differences in growth were calculated by the relative fluorescence of each strain when grown together at different starting ratios of

wild type:mutant *i.e.* 1:1 (black), 3:1 (white) or 1:3 (grey).

Figure 5. Homology models for the wild-type PfATP6 (I), ^{L263E}PfATP6 (II), ^{A623E}PfATP6 (III), and ^{S769N}PfATP6 (IV). The druggable pocket close to Leu263 is shown as reddish surface. The membrane position is shown as dots. The N and C terminals are shown as cyan sticks. The cytosolic domains are labeled as N , A, and P, indicating the nucleotide-binding domain, the actuator domain, and the phosphorylation site respectively.

Tables

Drug	K667[PfATP6] IC ₅₀ (95% CI)	K667Δ <i>pdr5</i> [PfATP6] IC ₅₀ (95% CI)	Fold difference
Artemisinin	10.6 (8.2 – 13.8)	1.8 (1.3 - 2.6)	6**
Artesunate	14.8 (10.0 – 21.9)	3.7 (2.9 - 4.7)	4*
Dihydroartemisinin	23.8 (16.9 – 33.7)	2.1 (1.6 - 2.8)	11**
Artemether	15.7 (12.5 – 19.7)	3.4 (2.8 - 4.1)	5***
Artemisone	3.6 (2.4 – 5.3)	0.9 (0.6 - 1.3)	4**

Table 1. IC₅₀ values for each artemisinin derivative for K667[PfATP6] and K667Δ*pdr5*[PfATP6]. Significant difference between wild type and *pdr5* knock-out for each derivative is indicated by asterisks (* p < 0.05 ; ** p < 0.005 ; *** p < 0.0005). Means are of three biological replicates.

Unassigned proteins	Mitochondrial	Also identified in <i>P. falciparum</i> (Wang, Ismail and Zhou)	Also identified in yeast protein-enriched vesicles
Adh1p alcohol dehydrogenase	6-phosphogluconate dehydrogenase	40S ribosomal protein S21	ABP PfATP6
Ahp1p	Acc1p Acetyl-CoA carboxylase	40S ribosomal protein S81	Arc1p tRNA delivery
Arc1p tRNA delivery	Acetyl-coenzyme A synthetase	ABP PfATP6	Elongation factor 1-alpha
Bgl2p endo-beta-1,3-glucanase	ATP synthase subunit alpha	Act1p actin	Hsp30p
Bmh1p	Cyc1p po-cytochrome c	ATP-dependent 6-phosphofructokinase	Plasma membrane ATPase
Bub2p	Cytochrome c oxidase subunit 2 (Fragment)	Elongation factor 1-alpha	DNA-directed RNA polymerase I subunit RPA43
Dur1,2p urea carboxylase/allophanate hydrolase	Glutamate decarboxylase	Eno2p	Rps11bp
Erg20p synthesizes the Rer2p substrate farnesyl diphosphate	Glyceroldehyde-3-phosphate dehydrogenase	Eukaryotic translation initiation factor 5A	Sec28p coatomer subunit epsilon
Gag	Malate dehydrogenase	Hsp104p	Yro2p
Nam9p	Pck1p phosphoenolpyruvate carboxykinase PCK1	Hsp12p	
Pdc1p Peroxisomal protein of unknown function	Pet9p ADP/ATP transporter	Hsp26p	
Rnr2p ribonucleotide-diphosphate reductase subunit RNR2	Phosphoglycerate kinase	Hsp30p	
Rpl10p ribosomal, chaperone	Por1p Mitochondrial outer membrane protein of unknown function	Ribosomal protein L19	
Rpl11ap	Pyruvate carboxylase	Rps18ap ribosomal subunit protein	
Rpl16bp	Pyruvate kinase	Ssa1p ATPase HSP70 family	
Rpl9ap	Qcr2p ubiquinol-cytochrome-c reductase subunit 2		
Rps14ap	Succinate dehydrogenase		
Ubi4p ubiquitin binding	Superoxide dismutase [Cu-Zn]		
Ugp1p UTP glucose-1-phosphate uridylyltransferase	Triosephosphate isomerase		
Uncharacterized protein			
Wtm1p Transcriptional modulator			

Table 2: Mass spectrometry results of all proteins pulled down by DHA-biotin from both PfATP6-expressing whole yeast and PfATP6 enriched microsomes. List is separated into unassigned proteins, mitochondrial proteins, those also pulled down from *P. falciparum* and human cancer cells, and those also identified in the yeast microsomes.